Prolonged Response to Regorafenib in a Patient with Iodine Refractory Thyroid Cancer
Thyroid cancer is the most common type of endocrine malignancy. Cornerstones of thyroid cancer treatment include surgery, radioactive iodine ablation, and thyroid stimulating hormone suppression. The National Comprehensive Cancer Network guidelines recommend two tyrosine kinase inhibitors for thyroi...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2019-10-01
|
| Series: | Case Reports in Oncology |
| Subjects: | |
| Online Access: | https://www.karger.com/Article/FullText/503419 |
| _version_ | 1819229671289520128 |
|---|---|
| author | Selina K. Wong Quincy S.C. Chu Jennifer L. Spratlin Randeep Sangha Alexander J.B. McEwan Donald W. Morrish Diane Arndt Gwen Sergenson Adriaan Cleton Funan Huang Michael B. Sawyer |
| author_facet | Selina K. Wong Quincy S.C. Chu Jennifer L. Spratlin Randeep Sangha Alexander J.B. McEwan Donald W. Morrish Diane Arndt Gwen Sergenson Adriaan Cleton Funan Huang Michael B. Sawyer |
| author_sort | Selina K. Wong |
| collection | DOAJ |
| description | Thyroid cancer is the most common type of endocrine malignancy. Cornerstones of thyroid cancer treatment include surgery, radioactive iodine ablation, and thyroid stimulating hormone suppression. The National Comprehensive Cancer Network guidelines recommend two tyrosine kinase inhibitors for thyroid cancer patients who are non-responsive to iodine: sorafenib and lenvatinib. Another oral kinase inhibitor, regorafenib, is not considered standard of care treatment for differentiated thyroid cancer. The chemical structures of regorafenib and sorafenib differ by a single fluorine atom. Given the significant improvement in progression-free survival (PFS) of sorafenib compared to placebo demonstrated in the phase 3 DECISION trial, we report on a patient with iodine-refractory follicular thyroid cancer treated with regorafenib as part of a phase 1 clinical trial. A 75 year old woman was diagnosed with follicular thyroid carcinoma in 2006 and initiated on treatment with regorafenib in 2011. She has completed 76 cycles with stable disease and pulmonary metastases 34% smaller than baseline. |
| first_indexed | 2024-12-23T11:16:53Z |
| format | Article |
| id | doaj.art-17f84ca3eeef446c9c88b10e69478f3b |
| institution | Directory Open Access Journal |
| issn | 1662-6575 |
| language | English |
| last_indexed | 2024-12-23T11:16:53Z |
| publishDate | 2019-10-01 |
| publisher | Karger Publishers |
| record_format | Article |
| series | Case Reports in Oncology |
| spelling | doaj.art-17f84ca3eeef446c9c88b10e69478f3b2022-12-21T17:49:11ZengKarger PublishersCase Reports in Oncology1662-65752019-10-0112379179510.1159/000503419503419Prolonged Response to Regorafenib in a Patient with Iodine Refractory Thyroid CancerSelina K. WongQuincy S.C. ChuJennifer L. SpratlinRandeep SanghaAlexander J.B. McEwanDonald W. MorrishDiane ArndtGwen SergensonAdriaan CletonFunan HuangMichael B. SawyerThyroid cancer is the most common type of endocrine malignancy. Cornerstones of thyroid cancer treatment include surgery, radioactive iodine ablation, and thyroid stimulating hormone suppression. The National Comprehensive Cancer Network guidelines recommend two tyrosine kinase inhibitors for thyroid cancer patients who are non-responsive to iodine: sorafenib and lenvatinib. Another oral kinase inhibitor, regorafenib, is not considered standard of care treatment for differentiated thyroid cancer. The chemical structures of regorafenib and sorafenib differ by a single fluorine atom. Given the significant improvement in progression-free survival (PFS) of sorafenib compared to placebo demonstrated in the phase 3 DECISION trial, we report on a patient with iodine-refractory follicular thyroid cancer treated with regorafenib as part of a phase 1 clinical trial. A 75 year old woman was diagnosed with follicular thyroid carcinoma in 2006 and initiated on treatment with regorafenib in 2011. She has completed 76 cycles with stable disease and pulmonary metastases 34% smaller than baseline.https://www.karger.com/Article/FullText/503419iodine-refractoryregorafenibthyroid cancer |
| spellingShingle | Selina K. Wong Quincy S.C. Chu Jennifer L. Spratlin Randeep Sangha Alexander J.B. McEwan Donald W. Morrish Diane Arndt Gwen Sergenson Adriaan Cleton Funan Huang Michael B. Sawyer Prolonged Response to Regorafenib in a Patient with Iodine Refractory Thyroid Cancer Case Reports in Oncology iodine-refractory regorafenib thyroid cancer |
| title | Prolonged Response to Regorafenib in a Patient with Iodine Refractory Thyroid Cancer |
| title_full | Prolonged Response to Regorafenib in a Patient with Iodine Refractory Thyroid Cancer |
| title_fullStr | Prolonged Response to Regorafenib in a Patient with Iodine Refractory Thyroid Cancer |
| title_full_unstemmed | Prolonged Response to Regorafenib in a Patient with Iodine Refractory Thyroid Cancer |
| title_short | Prolonged Response to Regorafenib in a Patient with Iodine Refractory Thyroid Cancer |
| title_sort | prolonged response to regorafenib in a patient with iodine refractory thyroid cancer |
| topic | iodine-refractory regorafenib thyroid cancer |
| url | https://www.karger.com/Article/FullText/503419 |
| work_keys_str_mv | AT selinakwong prolongedresponsetoregorafenibinapatientwithiodinerefractorythyroidcancer AT quincyscchu prolongedresponsetoregorafenibinapatientwithiodinerefractorythyroidcancer AT jenniferlspratlin prolongedresponsetoregorafenibinapatientwithiodinerefractorythyroidcancer AT randeepsangha prolongedresponsetoregorafenibinapatientwithiodinerefractorythyroidcancer AT alexanderjbmcewan prolongedresponsetoregorafenibinapatientwithiodinerefractorythyroidcancer AT donaldwmorrish prolongedresponsetoregorafenibinapatientwithiodinerefractorythyroidcancer AT dianearndt prolongedresponsetoregorafenibinapatientwithiodinerefractorythyroidcancer AT gwensergenson prolongedresponsetoregorafenibinapatientwithiodinerefractorythyroidcancer AT adriaancleton prolongedresponsetoregorafenibinapatientwithiodinerefractorythyroidcancer AT funanhuang prolongedresponsetoregorafenibinapatientwithiodinerefractorythyroidcancer AT michaelbsawyer prolongedresponsetoregorafenibinapatientwithiodinerefractorythyroidcancer |